PeptideDB

AF 399

CAS No.: 91533-02-7

AF 399 is a CCR4 antagonist. It reverses the tumor-promoting environment.
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Description AF 399 is a CCR4 antagonist. It reverses the tumor-promoting environment.
Synonyms AF399, AF-399
molecular weight 283.35
Molecular formula C12H17N3O3S
CAS 91533-02-7
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility DMSO: 55 mg/ml (194.11 mM)
References 1. Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ, Lip GYH, Chen SA. Oral Anticoagulation in Very Elderly Patients with Atrial Fibrillation - A Nationwide Cohort Study. Circulation. 2018 Feb 28. pii: CIRCULATIONAHA.117.031658. doi: 10.1161/CIRCULATIONAHA.117.031658. [Epub ahead of print] PubMed PMID: 29490992. 2. Conti S, Reiffel JA, Gersh BJ, Kowey PR, Wachter R, Halperin JL, Kaplon RE, Pouliot E, Verma A. Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF Study. J Atr Fibrillation. 2017 Feb 28;9(5):1551. doi: 10.4022/jafib.1551. eCollection 2017 Feb-Mar. PubMed PMID: 29250279; PubMed Central PMCID: PMC5673395. 3. Duytschaever M, Demolder A, Phlips T, Sarkozy A, El Haddad M, Taghji P, Knecht S, Tavernier R, Vandekerckhove Y, De Potter T. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. Eur Heart J. 2018 Apr 21;39(16):1429-1437. doi: 10.1093/eurheartj/ehx666. PubMed PMID: 29211857. 4. Chou PS, Ho BL, Chan YH, Wu MH, Hu HH, Chao AC. Delayed diagnosis of atrial fibrillation after first-ever stroke increases recurrent stroke risk: A 5-year nationwide follow-up study. Intern Med J. 2017 Nov 29. doi: 10.1111/imj.13686. [Epub ahead of print] PubMed PMID: 29193638.